Affordable Access

deepdyve-link
Publisher Website

Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.

Authors
  • Kast, R E
Type
Published Article
Journal
SpringerPlus
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Jan 01, 2015
Volume
4
Pages
638–638
Identifiers
DOI: 10.1186/s40064-015-1441-5
PMID: 26543772
Source
Medline
Keywords
License
Unknown

Abstract

Thus, dapsone has potential to both improve the quality of life in erlotinib treated patients by amelioration of rash as well as to short-circuit a growth-enhancing aspect of erlotinib when used in the anti-cancer role.

Report this publication

Statistics

Seen <100 times